Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Midatech Pharma stock

Own Midatech Pharma stock in just a few minutes.

Midatech Pharma plc is a biotechnology business based in the US. Midatech Pharma shares (MTP) are listed on the NASDAQ and all prices are listed in US Dollars. Midatech Pharma employs 65 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Midatech Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Midatech Pharma share price

Use our graph to track the performance of MTP stocks over time.

Midatech Pharma shares at a glance

Information last updated 2021-04-23.
52-week range$1.23 - $4.48
50-day moving average $2.13
200-day moving average $2.13
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.85

Buy Midatech Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Midatech Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Midatech Pharma financials

Revenue TTM $390,000
Gross profit TTM $-7,169,000
Return on assets TTM -32.28%
Return on equity TTM -151.13%
Profit margin 0%
Book value $0.58
Market capitalisation $25.7 million

TTM: trailing 12 months

Shorting Midatech Pharma shares

There are currently 179,515 Midatech Pharma shares held short by investors – that's known as Midatech Pharma's "short interest". This figure is 7.1% up from 167,636 last month.

There are a few different ways that this level of interest in shorting Midatech Pharma shares can be evaluated.

Midatech Pharma's "short interest ratio" (SIR)

Midatech Pharma's "short interest ratio" (SIR) is the quantity of Midatech Pharma shares currently shorted divided by the average quantity of Midatech Pharma shares traded daily (recently around 271992.42424242). Midatech Pharma's SIR currently stands at 0.66. In other words for every 100,000 Midatech Pharma shares traded daily on the market, roughly 660 shares are currently held short.

However Midatech Pharma's short interest can also be evaluated against the total number of Midatech Pharma shares, or, against the total number of tradable Midatech Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Midatech Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Midatech Pharma shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Midatech Pharma shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Midatech Pharma.

Find out more about how you can short Midatech Pharma stock.

Midatech Pharma share dividends

We're not expecting Midatech Pharma to pay a dividend over the next 12 months.

Have Midatech Pharma's shares ever split?

Midatech Pharma's shares were split on a 1:5 basis on 2 March 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Midatech Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Midatech Pharma shares which in turn could have impacted Midatech Pharma's share price.

Midatech Pharma share price volatility

Over the last 12 months, Midatech Pharma's shares have ranged in value from as little as $1.2254 up to $4.48. A popular way to gauge a stock's volatility is its "beta".

MTP.US volatility(beta: 1.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Midatech Pharma's is 1.8178. This would suggest that Midatech Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Midatech Pharma overview

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma. It also offers drug delivery platforms, such as Q-Sphera, a microencapsulation and polymer-depot sustained release drug delivery platform; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. Midatech Pharma plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site